Your browser doesn't support javascript.
loading
HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.
Beltjens, F; Bertaut, A; Pigeonnat, S; Loustalot, C; Desmoulins, I; Charon-Barra, C; Coudert, B; Fumoleau, P; Arveux, P; Arnould, L.
Afiliação
  • Beltjens F; Department of Pathology, Centre GF Leclerc, Dijon, France.
  • Bertaut A; Biostatistics and Epidemiology Unit, Centre GF Leclerc, Dijon, France.
  • Pigeonnat S; Department of Pathology, Centre GF Leclerc, Dijon, France.
  • Loustalot C; Department of Surgery, Centre GF Leclerc, Dijon, France.
  • Desmoulins I; Department of Medical Oncology, Centre GF Leclerc, Dijon, France.
  • Charon-Barra C; Department of Pathology, Centre GF Leclerc, Dijon, France.
  • Coudert B; Department of Medical Oncology, Centre GF Leclerc, Dijon, France.
  • Fumoleau P; Department of Medical Oncology, Centre GF Leclerc, Dijon, France.
  • Arveux P; Côte d'Or Breast Cancer Registry, Centre GF Leclerc, Dijon, France.
  • Arnould L; Department of Pathology, Centre GF Leclerc, Dijon, France.
Article em En | MEDLINE | ID: mdl-26503126

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Sistema de Registros / Carcinoma Lobular / Carcinoma Ductal de Mama / Receptor ErbB-2 Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Sistema de Registros / Carcinoma Lobular / Carcinoma Ductal de Mama / Receptor ErbB-2 Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article